Candriam S.C.A. Dyne Therapeutics, Inc. Transaction History

Candriam S.C.A.

$15.6 Billion
Q1 2025

A detailed history of Candriam S.C.A. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 463,368 shares of DYN stock, worth $6.59 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

463,368

Previous 401,395 15.44%

Holding current value

$6.59 Million

Previous $9.46 Million 48.75%

% of portfolio

0.03%

Previous 0.06%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$10.46 - $25.46 $648,237 - $1.58 Million	61,973 Added 15.44%	463,368 $4.85 Million
Q4 2024 Feb 06, 2025	BUY	$23.56 - $35.55 $245,942 - $371,106	10,439 Added 2.67%	401,395 $9.46 Million
Q3 2024 Nov 13, 2024	SELL	$31.94 - $47.04 $4.55 Million - $6.69 Million	-142,317 Reduced 26.69%	390,956 $14 Million
Q2 2024 Aug 05, 2024	SELL	$23.65 - $35.63 $3.37 Million - $5.07 Million	-142,351 Reduced 21.07%	533,273 $18.8 Million
Q1 2024 May 03, 2024	SELL	$13.06 - $29.18 $1.15 Million - $2.57 Million	-88,000 Reduced 11.52%	675,624 $19.2 Million
Q4 2023 Feb 14, 2024	BUY	$6.62 - $13.64 $264,800 - $545,600	40,000 Added 5.53%	763,624 $10.2 Million
Q2 2023 Aug 08, 2023	BUY	$8.53 - $14.28 $767,700 - $1.29 Million	90,000 Added 14.2%	723,624 $8.14 Million
Q4 2022 Feb 13, 2023	BUY	$9.37 - $13.8 $2.06 Million - $3.04 Million	220,000 Added 53.19%	633,624 $7.34 Million
Q2 2022 Aug 03, 2022	BUY	$4.36 - $10.5 $393,407 - $947,425	90,231 Added 27.9%	413,624 $2.84 Million
Q2 2021 Jul 20, 2021	BUY	$15.94 - $22.33 $5.15 Million - $7.22 Million	323,393 New	323,393 $6.8 Million

Others Institutions Holding DYN

# of Institutions

216

Shares Held

116M

Call Options Held

322K

Put Options Held

66.2K

View Full List

About Dyne Therapeutics, Inc.

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $737M
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

More about DYN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account